Table 1

Description of the patients recruited for the study
Samples Stage Grade Treatment cycles Age Overall survival
Ascites 1 IIIc High Grade Serous Carboplatin and Paclitaxel 6 cycle 39 years at diagnosis 3 years and 7 months
Doxorubicin Pegylated Liposomal 9 cycles
Gemcitabine and Carboplatin 3 cycles
Paclitaxel (12 treatments in cycle 1, 3 treatments in cycles 3 through to 9)
Ascites 2 IIa High Grade Serous Carboplatin 5 cycles 78 years at diagnosis 6 months
Ascites 3 Unknown Not Graded Carboplatin and Paclitaxel 4 cycles 59 years at diagnosis 5 months as of 20/11/2012
Ascites 4 Unknown Adenocarcinoma NOS Carboplatin and Paclitaxel 6 cycles 75 years at diagnosis 1 year 8 months
Tamoxifen 2 cycles
Doxorubicin Pegylated Liposomal 4 cycles
Ascites 5 IIc High Grade Serous Carboplatin and Paclitaxel 4 cycles, Topotecan 1 cycle 64 years at diagnosis 5 months
Ascites 6 IIIc High Grade Serous Carboplatin and Paclitaxel 6 cycles 52 years at diagnosis 2 years 5 months
AMG-386 182 Trial 8 cycles
Paclitaxel 3 cycles
Paragon Trial 2 cycles
Carboplatin single agent 3 cycles
Cyclophosphamide 2 cycles
Ascites 7 IIIc High Grade Serous Carboplatin and Paclitaxel 9 cycles 59 years at diagnosis 2 years 6 months
Cisplatin 4 cycles
Cyclophosphamide 2 cycles
Ascites 8 IV Adenocarcinoma NOS Carboplatin and Paclitaxel 6 cycles 67 years at diagnosis 2 years 6 months
Gemcitabine and Carboplatin 6 cycles
Ascites 9 Unknown Adenocarcinoma NOS Cyclophosphamide 3 cycles 2 years 8 months
Carboplatin and Paclitaxel 6 cycles 65 years at diagnosis
MORAb Trial 9 cycles
Doxorubicin Pegylated Liposomal 3 cycles
Ascites 10 IIIc High Grade Serous Doxorubicin Pegylated Liposomal 3 cycles 55 years 5 years 5 months
ICON 7 Trial 18 cycles
ICON 6 Trial 6 cycles
Paragon Trial 1 cycle
Paclitaxel 6 cycles
Ascites 11 IIIc High Grade Serous Hormonal Therapy Tamoxifen 69 years at diagnosis 7 years 11 months
Topotecan Hydrochloride 2 cycles
Carboplatin and Paclitaxel 6 cycles
Carboplatin single agent 6 cycles
Gemcitabine and Carboplatin 6 cycles
Carboplatin single agent 6 cycles
Cyclophosphamide 6 cycles
Doxorubicin Pegylated Liposomal 4 cycles
Paclitaxel 3 cycles
Ascites 12 IIIc High Grade Serous Doxorubicin Pegylated Liposomal 3 cycles Carboplatin and Paclitaxel 6 cycles 59 years at diagnosis 2 years 11 months as of 21/05/2013
Gemcitabine and Carboplatin 6 cycles
Ascites 13 IIIc High Grade Serous Doxorubicin Pegylated Liposomal 4 cycles 53 years at diagnosis 2 years 11 months as of 21/05/2013
Carboplatin and Paclitaxel 6 cycles
AMG-386 182 9 cycles
Paclitaxel 6 cycles
Cyclophosphamide 2 cycles
Topotecan 2 cycles
Ascites 14 IV High Grade Serous Carboplatin 1 cycle 46 years at diagnosis 2 years 6 months as of 13/08/2013
Carboplatin and Paclitaxel 6 cycles
Ascites 15 IIIc Not Graded Carboplatin 5 cycles 76 years at diagnosis 1 year and 8 months
Cyclophosphamide 7 cycles
Paragon Trial 3 cycles

NOS, Not Otherwise Specified.

Abubaker et al.

Abubaker et al. BMC Cancer 2014 14:317   doi:10.1186/1471-2407-14-317

Open Data